Loading...
Nolvadex, Soltamox
Antineoplastic • Selective estrogen receptor modulator (SERM)
Competitively inhibits estrogen binding to ER-positive breast cancer cells
Drug Class
Antineoplastic
Subclass
Selective estrogen receptor modulator (SERM)
Half-life
5-7 days
Time for plasma concentration to decrease by 50%
Protein Binding
>99%
Fraction bound to plasma proteins
Therapeutic Index
Wide
Margin between therapeutic and toxic doses